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Abstract
About 80 % of all women affected by ovarian cancer present with advanced stage disease at the time of diagnosis.
Achieving complete cytoreduction is complicated when many small tumor spots are found. Yet, complete
cytoreduction is the most important determinant of survival.
Application of a thermal plasma energy device to standard surgical instruments may help achieve complete
cytoreduction. The ‘PlasmaJet® Device’ (Plasma Surgical, Inc., Roswell, GA, USA) is an electrically neutral device which
emits a high–energy jet of argon plasma for direct tissue effects. We performed a literature review to investigate
whether the use of the ‘PlasmaJet® Device’ in surgery of advanced stage ovarian carcinoma (FIGO IIIB-IV) is effective
and safe.
The primary outcome was the proportion of complete cytoreductions. The secondary outcomes were: complication
rate, proportion of colostomies applied, histological findings, disease-free survival and overall survival.
Five case series or reports were found, including a total of 77 patients with FIGO stage IIIC-IV ovarian cancer in
whom the PlasmaJet® device was used for primary or interval debulking. Complete cytoreduction was obtained in
79% of the patients. Apart from one pneumothorax after extensive surgery, but no harm or additional
complications related to the use of the PlasmaJet® Device were reported. Data on disease-free survival or overall
survival were not reported.
These findings suggest that the PlasmaJet® Device is an efficient and safe innovative surgical device for debulking
surgery with encouraging results. We have proposed an RCT in which we will compare feasibility, safety and
effectiveness aspects of the use of the PlasmaJet® versus conventional electrosurgery in advanced stage epithelial
ovarian cancer (FIGO IIIB-IV).
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Introduction
Ovarian cancer is the fifth leading cause of cancer-re-
lated death among women and is the deadliest of gyne-
cologic cancers worldwide [1]. Eighty per cent of all
women affected by ovarian cancer present with advanced
stage disease at the time of diagnosis. The standard
treatment for advanced stage ovarian carcinoma is cytor-
eductive surgery combined with chemotherapy.
Complete cytoreductive surgery (CCS) is the most im-
portant determinant of prognosis and survival in advanced
stage ovarian carcinoma [2, 3]. The success rate of the op-
eration varies with factors such as patient selection and
morbidity, tumor location and surgeon’s expertise [4].
Novel surgical and chemotherapeutic treatments intro-
duced over the past decade have not led to significant im-
provement in survival.
Achieving complete cytoreduction is complicated
when many small tumor spots are found on the intes-
tines and the diaphragm. Conventional electrosurgery
then often does not result in complete removal of these
spots. A number of published case series suggest that
application of the ‘PlasmaJet® Device’ (Plasma Surgical,
Inc., Roswell, GA, USA) during cytoreductive surgery
results in higher rates of complete cytoreduction and
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lesser need of a colostomy. The device uses neutral argon
plasma to vaporize small tumor nodules with minimal col-
lateral damage [5, 6]. This technique seems to be effective
in tumor ablation; especially to remove peritoneal carcin-
omatosis on the abdominal peritoneum, in the diaphrag-
matic region, intestinal mesentery and bowel serosa.
Methods
We performed a literature review to investigate the ef-
fectiveness and safety of the use of the PlasmaJet® device
in surgery of advanced stage ovarian carcinoma (FIGO
IIIB-IV) based on CT scan. We aimed to compare the
outcomes of surgery with the additional use of the Plas-
maJet® device with the outcomes of conventional surgery
(using electrosurgery, scalpel, and scissors).
Primary outcome: percentage complete cytoreductive
surgery.
Secondary outcomes: complication rate, proportion of
colostomies applied, histological findings, disease-free
survival and overall survival.
The following databases were searched: https://www.
embase.com, https://www.controlled-trials.com, https://
www.clinicaltrials.gov, and https://www.york.ac.uk/inst/crd/
at December 2018. The search strategy was as follows:
((neutral NEAR/6 argon NEAR/6 plasma) OR (jet
NEAR/6 plasma NEAR/6 (coagulat* OR remov*)) OR
PlasmaJet):ab,ti.
The titles and abstracts of citations retrieved from the
search were screened on relevance by two authors (GN,
BK) independently. Study inclusion criteria were as fol-
lows: 1) Primary epithelial ovarian, fallopian tube or
peritoneal carcinoma, 2) FIGO stage IIB to IV, 3) pa-
tients treated with cytoreductive surgery, 4) residual dis-
ease categorized as complete (no macroscopic residual
disease), optimal (largest diameter 0,1–1 cm) and sub-
optimal (largest diameter > 1 cm) and 5) complication
rate reported.
Results
The search retrieved 84 citations. After screening of ti-
tles and abstracts six articles remained. After reading of
full texts by all authors, three case series and two case
reports were included (Table 1). Randomized controlled
trials on this topic were not found. Cordeiro et al. [7]
included 51 patients with FIGO stage IIIC-IV ovarian can-
cer in whom the PlasmaJet® device was used for primary/
interval debulking. Complete debulking was achieved in
40 (78%) patients. A pleural drain was needed in eight
(16%) patients in whom the PlasmaJet® was used for dia-
phragmatic stripping. No other post-operative complica-
tions were found. The authors did not provide data on
colostomies. Panuccio et al. [8] included 19 patients
undergoing primary/interval or secondary debulking for
ovarian cancer FIGO stage IIIC-IV. Complete debulking
was achieved in all 19 patients. A pneumothorax occurred
in one patient (5%). Bowel or urological fistulas did not
occur. Renaud et al. [9] described six patients who under-
went surgery with the PlasmaJet® device. Complete
debulking was achieved in one patient. The authors claim
that in none of these patients optimal debulking could
have been reached without the use of the device. Two case
studies by Seror and Butler-Manuel described the use of
PlasmaJet® without any complications [10, 11].
Discussion
The aggregated evidence from the five included studies
shows that complete cytoreduction was obtained in 79%
of the patients in whom the PlasmaJet® device was used
during surgery. Apart from one pneumothorax after ex-
tensive surgery, no other harm or complications possibly
related to the use of the PlasmaJet® device were
described.
Histological examination of lateral thermal spread and
the collateral tissue destruction caused by the use of the
PlasmaJet® device has been performed for different power
settings and exposure times. The lateral thermal spread
increased with increased power, while the depth of eschar
penetration remained relatively the same [4]. In a study in
pig, the use of the PlasmaJet® device was compared to lap-
aroscopic bipolar coagulation and surgical resection of the
peritoneum. Histological analysis 14 days after surgery
showed that all areas were equally destroyed; adhesions
were only seen in bipolar coagulation [4]. Sonoda et al., in-
vestigating the thermal damage of PlasmaJet® histologi-
cally, similarly concluded that minimal lateral damage and
depth of vaporization had occurred [6].
The use of the PlasmaJet® device in the removal of
rectal endometriosis showed promising results with no
Table 1 Studies using PlasmaJet for cytoreductive surgery in case of advanced stage ovarian cancer (FIGO IIIC-IV)
Author Number Debulking Complete debulking Colostomy Complications related to PlasmaJet
CordeiroVidal G [7] 51 Primary (41%) and interval (59%) 78% No data Pleural drain after diafragmatic stripping (n = 8)
Panuccio E [8] 19 Primary and interval 100% Pneumothorax (n = 1)
Bloodtransfusion (n = 5)
Renaud MC [9] 6 20% none
Seror J [10] 1 Primary Yes no None
Butler-Manuel S [11] 1 Interval Yes no Superficial wound defect
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major complications preventing colorectal resection. A
randomized controlled trial in sixty women undergo-
ing corrective abdominoplasty performed with either
conventional monopolar electrosurgery or the use of
the PlasmaJet® showed significantly fewer postopera-
tive complications (mainly wound infections), one day
earlier discharge, and better cosmetic outcomes with
the use of the PlasmaJet® device [12].
Conclusion
To our knowledge, this is the first systematic review on
the use of the PlasmaJet® Device in surgery of advanced
ovarian carcinoma. The available data suggest that the
device comes with several features that are well suited
for debulking surgery. Application of the device is effi-
cient in precise tissue dissection with minimal collateral
damage, especially when many small tumor spots are
found on the intestines and the diaphragm.
We have proposed an RCT named PlaComOv-study
in which we will compare feasibility, safety and effective-
ness aspects of the use of the PlasmaJet® with those of
conventional electrosurgery in advanced stage epithelial
ovarian cancer (FIGO IIIB-IV) [13]. We hypothesize that
the probability of achieving complete cytoreduction is
significantly higher in the group of patients randomized
to surgery with the use of the PlasmaJet® device. Second-
ary outcome include 30-days morbidity, ability to avoid
bowel surgery and stoma formation, quality of life and
cost-effectiveness.
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